We are 4-(1,2-Benzothiazol-3-yl)-1-[(3aR,7aR)-octahydro-2H-isoindol-2-yl ]piperazin-1-ium-1-sulfonate CAS:186204-37-5 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: 4-(1,2-Benzothiazol-3-yl)-1-[(3aR,7aR)-octahydro-2H-isoindol-2-yl ]piperazin-1-ium-1-sulfonate
trans-(R,R)-3a,7a-octahydroisoindolium-2-spiro-1'-[4'-(1,2-benzoisothiazole-3-yl)]piperazine methane sulfonate
Physical and Chemical Properties:
Boiling point: /
Melting point: /
Refractive index: /
Appearance: Off-white or white powder
Loss on drying:≤1.0%
Residue on ignition:≤0.5%
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Lurasidone hydrochloride CAS:367514-88-3
Intermediates of Lurasidone CAS:367514-87-2
Related News: After nearly ten years of growth, China’s fine chemical industry has made considerable progress. At present, China’s overall refinement rate (that is, the output value rate of fine chemicals = total value of fine chemical products / total value of chemical products * 100%) has reached about 40%. Some fine chemical products have certain international competitiveness and become important processing and exporting places of fine chemical raw materials and intermediates in the world.3-Chloropropyltrichlorosilane ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses.764-01-2 The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.2-bromo-6-fluorotolueno CAS:1422-54-4 The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.